No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.
Jalkanen, currently the group's chief operating officer, will take over from Dr Markku Jalkanen, who turns 70 later in 2024, with effect from 1 May.
"I am very happy that the AGM approved the proposals by the board of directors, creating an opportunity for the company to continue efforts on fundraising for a longer-term solution. I have worked for the company since its inception in 2006 and feel that now is the right time for me to retire as CEO of the company and leave the operative helm," said Dr Markku Jalkanen.
"The board and I have a plan for a seamless CEO transition and now is the time to make that move. I will continue to give my support to the company and the new CEO in my continuing role as board member. I also strongly believe in the promise of bexmarilimab to provide a new safe and effective cancer treatment option for a vast patient group, either as a stand-alone or combination therapy."
As of 0915 BST, Faron shares were up 1.47% at 134.45p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
